Table 5 PFS and OS of mRCC according to RECIST and Choi criteria

From: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

 

Median PFS a

Median OS

 

Months (range)

Months (range)

Response

 Choi criteria

Log rank=16.1, P<0.001

Log rank=20.0, P<0.001

Respondersb (n=36)

14.5

25.4

Non-respondersc (n=19)

3.2

10.4

 RECIST at first evaluation

Log rank=0.2, P=0.685

Log rank=1.7, P=0.191

Respondersb (n=7)

18.3

27.4

Non-respondersc (n=48)

9.0

13.2

 RECIST at best response

Log rank=11.2, P=0.001

Log rank=13.2, P<0.001

Respondersb (n=17)

19.3

31.3

Non-respondersc (n=38)

7.0

15.3

Clinical benefit

 RECIST

Log rank=63.2, P<0.001

Log rank=18.8, P<0.001

Clinical benefitd (n=41)a

12.2

22.3

No clinical benefite (n=13)

2.6

7.2

  1. Abbreviations: RECIST=Response Evaluation Criteria in Solid Tumours; PFS=progression-free survival; OS=overall survival.
  2. aFor one patient with stable disease, date of progressive disease was not available.
  3. bPartial response.
  4. cStable disease+progressive disease.
  5. dPartial response+stable disease ⩾12 weeks.
  6. eProgressive disease+stable disease <12 weeks.
Back to article page